Stroke-like episodes in OPA1 carriers require comprehensive work-up and therapeutic considerations

Metab Brain Dis. 2020 Feb;35(2):253-254. doi: 10.1007/s11011-019-00523-z. Epub 2019 Nov 28.

Abstract

This is a letter to the Editor concerning the recently published article by Zerem et al. The paper described a 12yo female with multisystem mitochondrial disorder (MID) due to the compound heterozygous variants c.1963_1964dupAT and p.Ile382Met in OPA1 manifesting phenotypically with congenital nystagmus, developmental delay, visual impairment, gait ataxia, epilepsy, a stroke-like episode (SLE) with encephalopathy and vomiting, and hearing impairment. This interesting case could be more meaningful by providing more information about the treatment of the SLE/stroke-like lesion (SLL), about the morphological characteristics of the SLL on MRI, and the results of prospective investigations for subclinical involvement of organs so far clinically unaffected.

Keywords: Mitochondrial disorder; Multiorgan; Optic atrophy; Oxidative phosphorylation; Respiratory chain; Stroke-like episode.

Publication types

  • Letter

MeSH terms

  • Anticonvulsants / therapeutic use
  • Child
  • Female
  • GTP Phosphohydrolases / genetics*
  • Heterozygote*
  • Humans
  • Mitochondrial Diseases / diagnosis
  • Mitochondrial Diseases / genetics
  • Mitochondrial Diseases / therapy
  • Neurologic Examination / methods*
  • Stroke / diagnosis*
  • Stroke / genetics*
  • Stroke / therapy

Substances

  • Anticonvulsants
  • GTP Phosphohydrolases
  • OPA1 protein, human